WO2006013441A2 - Use of probiotic bacteria for the preparation of topical compositions for skin protection - Google Patents
Use of probiotic bacteria for the preparation of topical compositions for skin protection Download PDFInfo
- Publication number
- WO2006013441A2 WO2006013441A2 PCT/IB2005/002235 IB2005002235W WO2006013441A2 WO 2006013441 A2 WO2006013441 A2 WO 2006013441A2 IB 2005002235 W IB2005002235 W IB 2005002235W WO 2006013441 A2 WO2006013441 A2 WO 2006013441A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probiotical
- composition
- preparation
- bacterium
- bacteria
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Definitions
- the present invention concerns the use of probiotical bacteria in the protection of the skin. More particularly, subject of the invention is the use of probiotical bacteria in the preparation of topical compositions for the treatment of the skin diseases caused by pathogens, especially recidivant infections or dermatitis-like diseases.
- the treatment of the cutaneous diseases caused by the proliferation of pathogens is conventionally carried out with antimicrobic medicaments, namely with pharmaceutical molecules with antibiotical and/or antimycotic action.
- Pityriasis versicolor is a very frequent infection.
- This infection caused by the fungus Malassezia furfur, very diffused among the youngest population, is not a serious pathology, but very bothering and generally shows a cyclic reappearing.
- M. furfur yeast plays an important role either in the seborrheic dermatitis (Bergbrant LM. e Faergemann J., Mycoses, 37(5- 6):217-219, 1994) and in the atopic dermatitis (Broberg A. e Faergemann J., Acta Derm Venereol., 75(1):46-49, 1995).
- Object of the present invention is to provide a new treatment for the affections of the skin caused by pathogens that does not exhibit the drawbacks of the prior art.
- object of the invention is to provide a treatment for the infections of the skin that is effective without risks for the patient and that reduces the occurence of recidives.
- object of the invention it was surprisingly found that it is possible to treat microbic diseases of the skin with probiotical bacteria obtaining in addition to the resolution of the infectious event, also the reduction of the risk of the occurence of recidives.
- subjectof the present invention is the use of probiotical bacteria for the preparation of a topical composition for the protection of the skin from the microbical diseases, in particular for preventing and/or treating the microbical diseases of the skin.
- subject of the invention is the use of probiotical bacteria for the preparation of a topical composition for preventing and/or treating the Pityriasis versicolor.
- subject of the invention is the use of probiotical bacteria for the preparation of a topical composition for preventing and/or treating dermatitis, in particular the atopic dermatitis.
- subject of the invention is the use of probiotical bacteria for preventing and/or treating dandruff.
- probiotical bacteria indicates bacteria able to have a beneficial effect on the host organism if taken in due amounts (Guarner F., Schaafsma G.J., Int. J. Food Microbiol.
- the preferred according to the invention are those belonging to the genus Lactobacillus.
- a probiotical bacterium particularly advantageous according to the present invention is L plantarum P 17630 commercialized under trademark
- Applicant for example Lgasseri P 18137, L.gasseri P17632 and the L crispatus P 17631.
- L. crispatus P17631 is highly effective in the treatment and in the prevention of the Pityriasis versicolor, also of the atopic dermatitis and its use in the preparation of products intended to such pathologies represents a preferred aspect of the present invention.
- the probiotical bacteria are used according to the invention in lyophilized form.
- the freeze-drying can be carried out according to any appropriate method, well known by those skilled in the art, optionally by using conventionally employed excipients.
- the probiotical bacteria according to the invention can be included in pharmaceutical or cosmetic compositions for topical use either ready for use or for extemporaneous formulations. Possible common additives and stabilisers can be added to said compositions or to the probiotical bacteria during the freeze-drying phase.
- subject of the invention is the use of probiotical bacteria in lyophilized form for the preparation of topical compositions for the prevention and/or the treatment of the microbical diseases of the skin.
- the probiotical bacteria according to the invention can be used under powder lyophilized form without being further manufactured o included in particular formulations.
- subject of the invention is the use of L. crispatus P17631 , advantageously in lyophilized form, for the preparation of a medicament for preventing and/or treating the infections caused by Pityriasis versicolor.
- the probiotical bacteria are in lyophilized form and are contained in pharmeceutical compositions for topical use, optionally in presence of conventional excipients and stabilisers.
- compositions comprising probiotical bacteria are a further subject of the invention.
- compositions can be medicaments or cosmetic products and can be prepared according to the methods known in the art and can be in a dosage unit form or a multiple dosage form.
- the compositions of the invention can be prepared under the form of gel, creams, emulsions, ointments, foams, powders, aqueous solutions or suspensions, oil solutions or suspensions or also biphasic solutions or suspensions, to be stirred before use.
- Compositions can contain between 10 3 and 10 12 , advantageously between 10 5 and 10 10 , for example between 10 6 and 10 8 CFU (colony-forming units) per gram of composition.
- compositions could be admnistered in appropriate amounts to the extent of the area to be treated, preferably one or more times a day.
- the treatment is preferably extended during at least 7-10 days, however also shorter treatments can provide interesting results.
- if desired or necessary longer treatments can be obviously foreseen. It has been also observed that in some cases it is advisable to carry out a "preventing" treatment in particular periods of the year, especially in the so- called “changes of season", namely in spring and autumn.
- probiotical bacteria according to the invention can also be carried out in connection with a conventional initial antimicrobic treatment, in order to accelerate the disappearing of the symptomatology (quick effect of the antimicrobic) and subsequently to limit the possibilities of relapses (long lasting effect of the probiotical bacteria).
- the invention concerns a method of treatment of the skin diseases as described above that comprises the topical administration of an effective dose of at least one probiotical bacterium.
- the types of the dermatological preparations that maintain a satisfactory vitality of the probiotics must contain a little water and must be lypophilic as for example the following:
- a biphasic liquid system emulsions, nanoemulsions, microemulsions
- oil in water emulsions, nanoemulsions, microemulsions
- Example 1 Formulation of a standard ointment that comprises at least:
- Surfactants for example sorbitan esters
- Example 3 Formulation of a standard gel that comprises at least Lyophilized lactobacillus
- the activity of the probiotical bacteria according to the invention has been demonstrated with in vitro and in vivo studies.
- the in vitro test used is the "agar spot test" described in many articles among which the one of Jacobsen CN. ET to. (Appl. and Envir. Microb. 65: 4949- 4956, 1999) and of Ouwehand A.C. ET to. (Letters in Applied Microbiology, 2003, 36:327-331).
- the dishes have been incubated at 37°C under aerobic conditions for 24-48 hours, until the patina growth of the pathogen was visible.
- the treatment has been performend by applying the lyophilized of L. crispatus extemporaneously suspended in an oleous mixture.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602005012276T DE602005012276D1 (en) | 2004-07-29 | 2005-07-28 | USE OF PROBIOTIC BACTERIA FOR THE PREPARATION OF TOPICAL COMPOSITIONS FOR THE PROTECTION OF THE SKIN |
EP05778952A EP1778258B1 (en) | 2004-07-29 | 2005-07-28 | Use of probiotic bacteria for the preparation of topical compositions for skin protection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2004A001550 | 2004-07-29 | ||
IT001550A ITMI20041550A1 (en) | 2004-07-29 | 2004-07-29 | USE OF PROBIOTIC BACTERIA FOR THE PREPARATION OF TOPICAL COMPOSITIONS FOR THE PROTECTION OF THE EPIDERMIS |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006013441A2 true WO2006013441A2 (en) | 2006-02-09 |
WO2006013441A3 WO2006013441A3 (en) | 2006-04-06 |
Family
ID=35058737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/002235 WO2006013441A2 (en) | 2004-07-29 | 2005-07-28 | Use of probiotic bacteria for the preparation of topical compositions for skin protection |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1778258B1 (en) |
AT (1) | ATE419859T1 (en) |
DE (1) | DE602005012276D1 (en) |
ES (1) | ES2320685T3 (en) |
IT (1) | ITMI20041550A1 (en) |
PT (1) | PT1778258E (en) |
WO (1) | WO2006013441A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2913337A1 (en) * | 2007-03-08 | 2008-09-12 | Oreal | Cosmetic treatment of keratinous material comprises providing a lyophilized form of live or inactive microorganism and a medium, extemporaneously contacting lyophilized form with medium and contacting the mixture with keratinous material |
WO2009000875A2 (en) * | 2007-06-27 | 2008-12-31 | Chr. Hansen A/S | Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis |
EP2149368A1 (en) * | 2008-07-29 | 2010-02-03 | L'oreal | Cosmetic use of microorganism(s) for the treatment of scalp disorders |
FR2945944A1 (en) * | 2009-06-02 | 2010-12-03 | Oreal | Use of as cosmetic agent of probiotic microorganism in particular of Lactobacillus and Bifidobacterium species genus, for treating scalp disorders e.g. dandruff condition, pruritis or seborrhoeic dermatitis |
WO2012150269A1 (en) * | 2011-05-03 | 2012-11-08 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
WO2012104025A3 (en) * | 2011-01-31 | 2013-01-17 | Merz Pharma Gmbh & Co. Kgaa | Balneotherapeutic lipid-containing probiotic preparations and their applications |
WO2014096641A1 (en) | 2012-12-17 | 2014-06-26 | Laboratoires Urgo | Method for preventing and/or treating infections, colonisations, or illnesses related to staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans and/or malassezia furfur |
EP2810641A1 (en) | 2013-05-31 | 2014-12-10 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent |
US9234204B2 (en) | 2012-08-07 | 2016-01-12 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
US9486513B1 (en) | 2010-02-09 | 2016-11-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9486487B2 (en) | 2014-10-31 | 2016-11-08 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
WO2017208172A1 (en) * | 2016-06-01 | 2017-12-07 | Probiotical S.P.A. | Bacteria-based gel compositions for topical applications and uses thereof |
US9878023B1 (en) | 2010-02-09 | 2018-01-30 | David Gordon Bermudes | Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US10064797B2 (en) | 2014-06-17 | 2018-09-04 | TopGeniX, Inc. | Topical formulations for UV protection |
US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
IT201800004036A1 (en) * | 2018-03-28 | 2019-09-28 | Teres Srl | TRANSDERMAL GEL |
WO2019226002A1 (en) * | 2018-05-23 | 2019-11-28 | 주식회사 고바이오랩 | Lactobacillus crispatus kbl693 strain and use thereof |
IT201900000801A1 (en) * | 2019-01-18 | 2020-07-18 | Proge Farm Srl | Composition including non-viable probiotic bacteria and its use in therapy |
US10857233B1 (en) | 2010-02-09 | 2020-12-08 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
WO2020249734A1 (en) * | 2019-06-13 | 2020-12-17 | Lactobio Aps | A gel composition comprising viable microorganisms |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
EP3755356A4 (en) * | 2018-02-24 | 2022-03-02 | Clearskin Ltd | Compositions, devices, systems, kits and methods for the treatment of a skin condition |
US11285183B2 (en) | 2018-05-23 | 2022-03-29 | Kobiolabs, Inc. | Lactobacillus gasseri KBL697 strain and use thereof |
US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3436156A1 (en) | 2016-03-31 | 2019-02-06 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
FR3117340B1 (en) * | 2020-12-15 | 2024-01-05 | Basf Beauty Care Solutions France Sas | Cosmetic, nutraceutical or dermatological use of a strain of Lactobacillus crispatus and/or of a composition comprising it |
WO2023105040A1 (en) * | 2021-12-10 | 2023-06-15 | Biotix PTE LTD | Composition comprising lactobacillus crispatus bacterial lysates and/or bacteria for improving skin condition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258355B1 (en) * | 1996-11-22 | 2001-07-10 | Vsl Pharmaceuticals Inc. | Sphingomyelinase compositions and use thereof |
US20030049231A1 (en) * | 1999-12-22 | 2003-03-13 | Markus Baur | Agent for the anti-adhesion of skin pathogenic flora |
-
2004
- 2004-07-29 IT IT001550A patent/ITMI20041550A1/en unknown
-
2005
- 2005-07-28 PT PT05778952T patent/PT1778258E/en unknown
- 2005-07-28 WO PCT/IB2005/002235 patent/WO2006013441A2/en active Application Filing
- 2005-07-28 ES ES05778952T patent/ES2320685T3/en active Active
- 2005-07-28 DE DE602005012276T patent/DE602005012276D1/en active Active
- 2005-07-28 EP EP05778952A patent/EP1778258B1/en not_active Not-in-force
- 2005-07-28 AT AT05778952T patent/ATE419859T1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258355B1 (en) * | 1996-11-22 | 2001-07-10 | Vsl Pharmaceuticals Inc. | Sphingomyelinase compositions and use thereof |
US20030049231A1 (en) * | 1999-12-22 | 2003-03-13 | Markus Baur | Agent for the anti-adhesion of skin pathogenic flora |
Non-Patent Citations (1)
Title |
---|
ROSENFELDT V ET AL: "EFFECT OF PROBIOTIC LACTOBACILLUS STRAINS IN CHILDREN WITH ATOPIC DERMATITIS" February 2003 (2003-02), JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, PAGE(S) 389-395 , XP008023585 ISSN: 0091-6749 the whole document * |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2913337A1 (en) * | 2007-03-08 | 2008-09-12 | Oreal | Cosmetic treatment of keratinous material comprises providing a lyophilized form of live or inactive microorganism and a medium, extemporaneously contacting lyophilized form with medium and contacting the mixture with keratinous material |
WO2009000875A2 (en) * | 2007-06-27 | 2008-12-31 | Chr. Hansen A/S | Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis |
WO2009000875A3 (en) * | 2007-06-27 | 2009-12-23 | Chr. Hansen A/S | Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis |
EP2149368A1 (en) * | 2008-07-29 | 2010-02-03 | L'oreal | Cosmetic use of microorganism(s) for the treatment of scalp disorders |
WO2010013182A1 (en) * | 2008-07-29 | 2010-02-04 | L'oreal | Cosmetic use of microorganism(s) for the treatment of scalp disorders |
FR2945944A1 (en) * | 2009-06-02 | 2010-12-03 | Oreal | Use of as cosmetic agent of probiotic microorganism in particular of Lactobacillus and Bifidobacterium species genus, for treating scalp disorders e.g. dandruff condition, pruritis or seborrhoeic dermatitis |
US10857233B1 (en) | 2010-02-09 | 2020-12-08 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US10954521B1 (en) | 2010-02-09 | 2021-03-23 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US10364435B1 (en) | 2010-02-09 | 2019-07-30 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9878023B1 (en) | 2010-02-09 | 2018-01-30 | David Gordon Bermudes | Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US11219671B1 (en) | 2010-02-09 | 2022-01-11 | David Gordon Bermudes | Protease inhibitor:protease sensitive expression system, composition and methods for improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9486513B1 (en) | 2010-02-09 | 2016-11-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
WO2012104025A3 (en) * | 2011-01-31 | 2013-01-17 | Merz Pharma Gmbh & Co. Kgaa | Balneotherapeutic lipid-containing probiotic preparations and their applications |
WO2012150269A1 (en) * | 2011-05-03 | 2012-11-08 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
US10555977B2 (en) | 2011-05-03 | 2020-02-11 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
US10729732B2 (en) | 2012-02-29 | 2020-08-04 | Ethicon Endo Surgery, Inc. | Compositions of microbiota and methods related thereto |
US9453232B2 (en) | 2012-08-07 | 2016-09-27 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
US9868957B2 (en) | 2012-08-07 | 2018-01-16 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
US9234204B2 (en) | 2012-08-07 | 2016-01-12 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
WO2014096641A1 (en) | 2012-12-17 | 2014-06-26 | Laboratoires Urgo | Method for preventing and/or treating infections, colonisations, or illnesses related to staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans and/or malassezia furfur |
EP2810641A1 (en) | 2013-05-31 | 2014-12-10 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US10828350B1 (en) | 2014-02-14 | 2020-11-10 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US10064797B2 (en) | 2014-06-17 | 2018-09-04 | TopGeniX, Inc. | Topical formulations for UV protection |
US11213556B2 (en) | 2014-10-31 | 2022-01-04 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11278580B2 (en) | 2014-10-31 | 2022-03-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11931387B2 (en) | 2014-10-31 | 2024-03-19 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US9486487B2 (en) | 2014-10-31 | 2016-11-08 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10675312B2 (en) | 2014-10-31 | 2020-06-09 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US11364270B2 (en) | 2014-10-31 | 2022-06-21 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10842830B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
US10842831B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
WO2017208172A1 (en) * | 2016-06-01 | 2017-12-07 | Probiotical S.P.A. | Bacteria-based gel compositions for topical applications and uses thereof |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
EP3755356A4 (en) * | 2018-02-24 | 2022-03-02 | Clearskin Ltd | Compositions, devices, systems, kits and methods for the treatment of a skin condition |
US11918825B2 (en) | 2018-02-24 | 2024-03-05 | Clearskin Ltd. | Compositions, devices, systems, kits and methods for the treatment of a skin condition |
IT201800004036A1 (en) * | 2018-03-28 | 2019-09-28 | Teres Srl | TRANSDERMAL GEL |
WO2019226002A1 (en) * | 2018-05-23 | 2019-11-28 | 주식회사 고바이오랩 | Lactobacillus crispatus kbl693 strain and use thereof |
KR20190133639A (en) * | 2018-05-23 | 2019-12-03 | 주식회사 고바이오랩 | Lactobacillus Crispatus KBL693 and Use Thereof |
JP2021524747A (en) * | 2018-05-23 | 2021-09-16 | コ・バイオラブズ・インコーポレイテッド | Lactobacillus crispatus KBL693 strain and its use |
CN112384611A (en) * | 2018-05-23 | 2021-02-19 | Ko生物技术有限公司 | Lactobacillus crispatus KBL693 strain and application thereof |
CN112384611B (en) * | 2018-05-23 | 2024-01-09 | Ko生物技术有限公司 | Lactobacillus crispatus KBL693 strain and application thereof |
US11285183B2 (en) | 2018-05-23 | 2022-03-29 | Kobiolabs, Inc. | Lactobacillus gasseri KBL697 strain and use thereof |
EP3798299A4 (en) * | 2018-05-23 | 2022-03-30 | Ko Biolabs, Inc. | Lactobacillus crispatus kbl693 strain and use thereof |
AU2019274350B2 (en) * | 2018-05-23 | 2022-04-07 | Kobiolabs, Inc. | Lactobacillus crispatus KBL693 strain and use thereof |
EP3798298A4 (en) * | 2018-05-23 | 2022-05-11 | Kobiolabs, Inc. | Lactobacillus gasseri kbl697 strain and use thereof |
US11141444B2 (en) | 2018-05-23 | 2021-10-12 | Ko Biolabs, Inc. | Lactobacillus crispatus KBL693 strain and use thereof |
US11819526B2 (en) | 2018-05-23 | 2023-11-21 | Kobiolabs, Inc. | Lactobacillus Gasseri KBL697 strain and use thereof |
JP2022140631A (en) * | 2018-05-23 | 2022-09-26 | コバイオラブズ・インコーポレイテッド | Lactobacillus crispatus KBL693 strain and use thereof |
KR102138832B1 (en) * | 2018-05-23 | 2020-07-29 | 주식회사 고바이오랩 | Lactobacillus Crispatus KBL693 and Use Thereof |
US11633439B2 (en) | 2018-05-23 | 2023-04-25 | Kobiolabs, Inc. | Lactobacillus crispatus KBL693 strain and use thereof |
EP3682890A1 (en) * | 2019-01-18 | 2020-07-22 | Proge Farm S.r.l. | Composition comprising non-viable probiotic bacteria and its use in therapy |
IT201900000801A1 (en) * | 2019-01-18 | 2020-07-18 | Proge Farm Srl | Composition including non-viable probiotic bacteria and its use in therapy |
US20220233614A1 (en) * | 2019-06-13 | 2022-07-28 | Lactobio A/S | Gel composition comprising viable microorganisms |
WO2020249734A1 (en) * | 2019-06-13 | 2020-12-17 | Lactobio Aps | A gel composition comprising viable microorganisms |
Also Published As
Publication number | Publication date |
---|---|
EP1778258B1 (en) | 2009-01-07 |
ATE419859T1 (en) | 2009-01-15 |
ES2320685T3 (en) | 2009-05-27 |
ITMI20041550A1 (en) | 2004-10-29 |
WO2006013441A3 (en) | 2006-04-06 |
DE602005012276D1 (en) | 2009-02-26 |
PT1778258E (en) | 2009-03-31 |
EP1778258A2 (en) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1778258B1 (en) | Use of probiotic bacteria for the preparation of topical compositions for skin protection | |
US10449222B2 (en) | Method for preventing and/or treating infections, colonisations, or illnesses related to Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis, Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and/or Malassezia furfur | |
DK2704704T3 (en) | PROBIOTIC BACTERIES FOR TOPICAL TREATMENT OF SKIN DISORDERS | |
EP2364712A1 (en) | Topical cosmetic or pharmaceutical composition comprising probiotic lactobacillus strains and use of same | |
JP2002512615A (en) | Topical use of symbiotic Bacillus spores to prevent or control microbial infection | |
JPWO2009084200A1 (en) | External skin preparation for acne skin | |
JP2001172176A (en) | Skin improver | |
KR20090038648A (en) | A composition using the cosmetic containing chamaecyparis obtusa oil for a pimpled skin | |
US20010018060A1 (en) | Use of particular fatty substances which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter | |
KR102270709B1 (en) | Cosmetic composition for skin improvement containing complex ceramide and natural extracts | |
JP2007176798A (en) | Liquid external preparation for skin comprising stable glutathione and liquid external preparation for skin for bleaching and beautifying skin comprising the same | |
JPH01311014A (en) | Antimicrobial skin drug for external use | |
KR102031359B1 (en) | Composition for improving microbial flora containing extract of Rosae Multiflorae fructus | |
WO2014106541A1 (en) | Dermal composition for use in the external genital area in females | |
KR102293592B1 (en) | Skin external composition comprising extract of Martensia jejuensis and functional food comprising extract of Martensia jejuensis | |
KR102031354B1 (en) | Composition for improving microbial flora containing extract of cinnamomi ramulus | |
KR102001241B1 (en) | Composition for improving microbial flora containing extract of Coicis Semen | |
KR102031351B1 (en) | Composition for improving microbial flora containing extract of Trigonellae semen | |
JPS59175426A (en) | Cariostatic agent | |
KR102031360B1 (en) | Composition for improving microbial flora containing extract of violae herba | |
KR102031362B1 (en) | Composition for improving microbial flora containing extract of Allii Fistulosi bulbus | |
KR102031355B1 (en) | Composition for improving microbial flora containing extract of Angelica gigas root | |
KR102054911B1 (en) | Composition for Improving Microbial Flora containing Amygdalin | |
KR102001244B1 (en) | Composition for improving microbial flora containing extract of Carthami Fructus | |
KR102031361B1 (en) | Composition for improving microbial flora containing extract of Lepidii seu Descurainiae semen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005778952 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005778952 Country of ref document: EP |